The success of gene therapies to date continues to spark an exciting second wave that is laying the foundation for next-generation technologies across several therapeutic areas—oncology, cardiovascular, muscular disorders, neurological conditions, and others.
To confirm our suspicions of an upward tick in the number of gene therapy programs initiated year over year, we turned to Citeline for a glimpse at the real figures.
Not surprisingly, early phase research is where we see the majority of gene therapy trials. However, it is interesting to see that Phase I/II combination studies are the dominant early phase design choice for gene therapies. We recently wrote an article about best practices for executing Phase I/II combination studies, which may be helpful in your upcoming planning and considerations.
The gene therapy segment is busier than ever, with more than 120 open trials (Trialtrove® JAN 2022–AUG 2022). Citeline maintains a dedicated team of analysts who keep a keen eye on the number of planned clinical trials across the industry. Based on their tracking, we can see that Citeline Trialtrove® identified an additional 53 gene therapy trials on the horizon (see table below).
When diving deeper into the 128 presently open gene therapy clinical trials (as of AUG 2022), we see cardiovascular and CNS as the leading therapeutic areas with 26 clinical trials each (see table below). These are immediately followed by ophthalmology, oncology, and metabolic/endocrinology.
In examining the 128 presently open gene therapy clinical trials (as of AUG 2022), we gain a clearer picture of which diseases are drawing the most interest from sponsors (see table below).
The regulatory pathway for Gene Therapies has, of course, its unique nuances. We thought it worthwhile to pause and look at the top 20 countries with active gene therapy clinical trials. If you have access to Citeline, you can further investigate which trials and indications are active within each of the countries listed below.
In the future, genetic therapies may be used to prevent, treat, or cure certain inherited disorders, cancers, or infections. Promising early results and the potential of these therapies are driving the growth of this new category of personalized medicine. We want to thank the dedicated team of analysts at Citeline, without whom this analysis could not have been completed.
If you are interested in digging further into the analysis of the information covered above, you can do so by leveraging this link to the Trialtrove® research.
The realization of next-generation cell and gene therapies calls for more specialized support. Through Precision ADVANCE, your next project can take advantage of an intelligently designed combination of clinical, manufacturing, and commercialization solutions specific for cell and gene therapy development.
For more information on Precision ADVANCE, contact us.
Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
